For the new feature for the diagnosis of Covid-19 rapid test saliva spoke on the THEME 104,6 the director of development of the Newpharm A.E., Constantine Αργυρίδης.
As explained by mr Αργυρίδης, “it is a simple process. The reliability is 95%, just as high as it is and the nasopharyngeal test. It is very more high, and many tests through the nose”.
“The detection of asymptomatic is the strategy that must be followed by every government, so in order to reduce the spread of the virus. And this test gives us new possibilities because we can do small children, they can be widely used tests, to everyone,” added mr. Αργυρίδης, noting that “with 37 studies that have been summarized in a deductive analysis was made on 12 January in 7.169 people, we see that the reliability of the saliva test is the same, has substantial differences with the nasopharyngeal”.
“If there was the ability to do up to two tests per month each, we would be able to contain the virus by 80% within 1 – 1,5 month,” he added.